Could ADCs go beyond FRα and HER2 in #OvarianCancer?.In 80 HGSOC samples:.✅FR@: 72%.✅HER2:%83.✅ CDH6: 72%.✅ TROP2: 78%.✅ B7-H4: 78%. 💥 91% of FRα/HER2-negative tumors expressed ≥1 other target.#ESMOGynae25 #OncoTwitter @OncoAlert

🚨 New Study Alert!.Real-world data from 88 patients with BRAF-mutant #NSCLC:.✅ First-line dabrafenib + trametinib shows superior ORR & PFS vs. chemo. 🧠 Read more in Clinical Lung Cancer: [DOI: 10.1016/j.cllc.2025.07.015].#LungCancer #BRAF #OncoTwitter #NSCLCResearch

Thrilled to share that our abstract has been accepted for poster presentation at the ASCO Quality Care Symposium 2025!.Grateful for the opportunity to contribute to quality improvement in oncology care. #ASCOQLTY25 #OncoTwitter #CancerEpidemiology #LungCancer.@oncodaily @ASCO

Science progresses, but if patients can’t access it, we fail. We must bridge the gap between innovation and reality. #ASCO25 #mTNBC #OncoTwitter.@oncodaily @ASCO

IO + chemo, dual IO, bevacizumab blends we’ve recycled every route. Yet 5 year OS still stalls at 25–30%. This narrative review says:.Stop chasing the same horizon. Winter won't end unless we reimagine the sun. Shift the axis. #NSCLC #OncoTwitter

Hello #medtwitter #med #skin #oncotwitter 👋 . Happy Sunday ! . Before 🇮🇳 v 🇵🇰 🏏 . Let’s discuss! . Beyond chief complaints. Spot diagnosis?.Rx of choice?. #MedX #MedTwitter

Case 111: with @BhaveshPopat7 @rohankhadtare . 48/M; presentation right flank pain; CT scan s/o large right Angiomyolipoma AML with bleed: intra-lesional aneurysm; pre-Sx embo with combination of glue; PVA and coils; images 👇 . #irad #medtwitter #meded #oncotwitter #radiology

🚨 FAERS database study highlights neurotoxicities in myeloma patients receiving bispecifics & CAR-T therapies. Important signal detection for AE vigilance. #Myeloma #Neurotoxicity #CAR_T #Bispecifics #FAERS #OncoTwitter #المايلوما #السرطان @atif_khanktk @Abdallah81MD.

Uncommon EGFR mutations in NSCLC often fly under the radar. This is one slide showing the first-line data for uncommon EGFR mutations — from 4 trials - ACHILLES, UNICORN, KCSG-lu15-09 , and CHRYSALIS-2 ( cohort C ) #oncotwitter #uncomonEGFR #LCSM @OncoAlert @OncBrothers

Just wrapped up a great mentoring session at the TECAG Lounge at #ASCO25 and yes, they had açaí! 🍧 Thoughtful planning, great conversations, and a must-visit spot during the conference. 👏 #OncoTwitter #Mentorship #ASCO2025 @ASCOTECAG

Watch & Wait in rectal cancer: @JCO_ASCO study:.Distant mets in local regrowth pts = 22.8%.vs. 10.2% in TME pts (P≤.001).LR → higher risk of mets even if salvageable. DM-free survival: 75% vs. 87%.Should we rethink our Watch & Wait strategy?. #OncoTwitter @ESMO @ASCO @Larvol

🚀🔥Dinner with some of the world’s top radiation oncologists in GU tumors at #ESTRO25. Talent, friendship, and shared purpose — it felt like the Oscars of GU radiotherapy!. #RadiationOncology #GUOnc #TeamScience #OncoTwitter

🆕 Review in Frontiers in Oncology Reviews.📌 Triplet therapy in mHSPC 💉💊🧬.Critically assessed in a GUARD-led multidisciplinary paper.🙏 Proud co-author!.🔗 #ProstateCancer #mHSPC #TripletTherapy #OncoTwitter 🔬👨‍⚕️👩‍⚕️ @GUARDconsortium

📢 Excited to participate in Cancer Research Methodology Workshop at @KtmCancerCenter .Fantastic insights on study design, biostats & clinical research. Huge thanks to @OncoAlert & @SimitSapkota for bringing this program to Kathmandu #Nepal. #OncoTwitter #CancerResearch #MedEd

Kicking off Day 2 of #ASCO25 with a spotlight on follow-up care after #BreastCancer @ines_vazluis shares how personalized survivorship plans and #AI tools can support patients and providers 🤝💻. Advancing care as we advance technology #OncoTwitter #CancerSurvivorship

DESTINY-Breast11 showed Enhertu→THP outperformed ddAC→THP in early HER2+ BC. But many centers already use TCHP instead of ddAC. Do you think results would differ if it was compared to TCHP instead?. #oncotwitter #BreastCancer#Enhertu .⁦@OncoAlert

Antibody–Drug Conjugates (ADCs) in SCLC.All active agents in 2L/3L+ setting—DLL3, B7-H3, SEZ6, TROP2—summarized in one slide. Includes payloads, companies,trials, ORR/PFS/OS, and toxicity profile .Which one you think is most promising one #OncoTwitter.@OncoAlert @dr_yakupergun

Social media in oncology is a double-edged sword: it can democratize knowledge and amplify diverse voices, but also risks promoting visibility over rigor. A superb comment—one of the best examples of meaningful social media use! 👏🏻👏🏻 #OncoTwitter #DigitalOncology.

Case 76: with @BhaveshPopat7. Intravascular foreign body removal; broken chemoport tubing; removal with combination of pigtail + snare. #irad #MedTwitter #MedEd #oncotwitter #vasculartwitter #radres #cardiotwitter #interventionalradiology

📱Watch the video with the latest on translational NEN research by Dr. Mauro Cives @cives_mauro – now with captions in French, German, Italian, Portuguese and Spanish: #LetsTalkAboutNETs #MedTwitter #OncTwitter #OncoTwitter